Abstract
<div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://bioinsights.blob.core.windows.net/uploads/Thirkettle colour 2020 copy.jpg" data-image="1"></div><div class="author-det"> <b>Jan Thirkettle</b> is Chief Executive Officer of Transine Therapeutics, UK based biotech developing SINEUPs (a novel lncRNA platform which upregulates protein expression) in ocular and neurodegenerative diseases. He was previously Chief Development Officer at Freeline, a clinical phase AAV gene therapy company with a novel AAV capsid platform. Jan has extensive experience in the devel¬opment and commercialisation of novel platforms including NCEs, natural products, biologics and gene therapies, and has played a role in launching products in all these classes. Prior to joining Freeline Jan led the establishment of GSK’s Cell and Gene Therapy platform and was responsible for CMC/sup¬ply for Strimvelis, the first <i>ex vivo</i> gene therapy to receive an EU Marketing Authorisation Application. Jan holds an MA in Chemistry and a PhD in Biological Chemistry from Oxford University. </div></div></div>
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
